Reuters logo
BRIEF-Moleculin Biotech says working to resubmit IND application for annamycin
May 23, 2017 / 11:42 AM / 4 months ago

BRIEF-Moleculin Biotech says working to resubmit IND application for annamycin

May 23 (Reuters) - Moleculin Biotech Inc

* Moleculin Biotech issues shareholder update on FDA designation of orphan drug and IND status for annamycin

* Moleculin Biotech - working to resubmit IND application for annamycin and to announce co may begin Phase I/II clinical trials by end of July of 2017

* Moleculin Biotech - if unable to obtain CMC data on timely basis,will delay resubmitting ind application for annamycin,which will delay clinical trials Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below